News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Xencor And Chugai Pharmaceutical Co., Ltd. (Japan) Initiate Partnership For Optimized Antibodies; Chugai Licenses Xencor's XmAb Technology To Enhance Antibody Efficacy


10/19/2005 5:12:04 PM

MONROVIA, Calif.--(BUSINESS WIRE)--Jan. 10, 2005--Xencor today announced a license and collaboration agreement with Chugai Pharmaceutical Co., Ltd. (Chugai) to create monoclonal antibodies with greatly enhanced potency. Chugai will use Xencor's XmAb(TM) technology on Chugai's antibodies against a proprietary cancer target. The XmAb technology consists of a suite of engineered antibody Fc domains that can be applied to any antibody to control the recruitment of the immune system's effector functions and to greatly increase antibody-mediated tumor killing.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES